Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells

Cytotherapy

Volumn 17, Issue 2, 2015, Pages 174-185

  Raicevic, Gordana ^a   Najar, Mehdi ^a   Najimi, Mustapha ^b   El Taghdouini, Adil ^c   van Grunsven, Leo A ^c   Sokal, Etienne ^b   Toungouz, Michel ^a,d  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d ERASME HOSPITAL   (Belgium)

Author keywords

Adult derived human liver stem cells; Cell adhesion molecules; Inflammation; Stellate cells; Toll like receptors

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; B7 ANTIGEN; CD115 ANTIGEN; CD134 ANTIGEN; CD34 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD86 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA G ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MESSENGER RNA; NECTIN 2; OX40 LIGAND; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; COLONY STIMULATING FACTOR RECEPTOR; IL2RB PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR BETA; TOLL LIKE RECEPTOR;

ADOLESCENT; ADULT; ADULT DERIVED HUMAN LIVER STEM CELL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW MESENCHYMAL STROMAL CELL; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOREGULATION; INFANT; INFLAMMATION; LIVER CELL; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STROMA CELL; NEWBORN; PROTEIN EXPRESSION; STELLATE CELL; T LYMPHOCYTE ACTIVATION; BIOLOGICAL THERAPY; BIOSYNTHESIS; BONE MARROW CELL; CYTOLOGY; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; LIVER; LIVER DISEASES; LYMPHOCYTE ACTIVATION; METABOLISM;

ANTIGENS, CD274; ANTIGENS, CD34; ANTIGENS, CD45; BIOMARKERS; BONE MARROW CELLS; CELL- AND TISSUE-BASED THERAPY; HEMATOPOIETIC STEM CELLS; HEPATIC STELLATE CELLS; HLA-G ANTIGENS; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; INFLAMMATION; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; LIVER; LIVER DISEASES; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; TOLL-LIKE RECEPTORS;

EID: 84922505648     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.10.001     Document Type: Article

References (66)

1. Strom S.C., Fisher R.A., Thompson M.T., Sanyal A.J., Cole P.E., Ham J.M., et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 1997, 63:559-569.
2. Muraca M., Gerunda G., Neri D., Vilei M.T., Granato A., Feltracco P., et al. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002, 359:317-318.
3. Sokal E.M., Smets F., Bourgois A., Van Maldergem L., Buts J.P., Reding R., et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation 2003, 76:735-738.
4. Stephenne X., Najimi M., Sibille C., Nassogne M.C., Smets F., Sokal E.M. Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency. Gastroenterology 2006, 130:1317-1323.
5. Dollé L., Best J., Mei J., Battah F.A., Reynaert H., van Grunsven L.A. The quest for liver progenitor cells: A practical point of view. JHepatol 2010, 52:117-129.
6. Russo F.P., Parola M. Stem and progenitor cells in liver regeneration and repair. Cytotherapy 2011, 13:135-144.
7. Sato M., Suzuki S., Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct 2003, 28:105-112.
8. Friedman S.L. Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver. Physiol Rev 2008, 88:125-172.
9. Pinzani M., Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001, 21:397-416.
10. Van Beneden K., Mannaerts I., Pauwels M., Van den Branden C., van Grunsven L.A. HDAC inhibitors in experimental liver and kidney fibrosis. Fibrogenesis & Tissue Repair 2013, 6:1.
11. Najimi M., Khuu D.N., Lysy P.A., Jazouli N., Abarca J., Sempoux C., et al. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes?. Cell Transplant 2007, 16:717-728.
12. Fang B., Shi M., Liao L., Yang S., Liu Y., Zhao R.C. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 2009, 78:83-88.
13. Wang J., Bian C., Liao L., Zhu Y., Li J., Zeng L., et al. Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res 2009, 39:1219-1228.
14. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
15. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 2008, 36:733-741.
16. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
17. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003, 31:890-896.
18. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
19. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105:4120-4126.
20. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005, 105:2214-2219.
21. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
22. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
23. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
24. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
25. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003, 5:485-489.
26. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
27. Spaggiari G.M., Abdelrazik H., Becchetti F., Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009, 113:6576-6583.
28. Meisel R., Brockers S., Heseler K., Degistirici O., Bulle H., Woite C., et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 2011, 25:648-654.
29. Najar M., Raicevic G., Boufker H.I., Fayyad Kazan H., De Bruyn C., Meuleman N., et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010, 264:171-179.
30. Najar M., Raicevic G., Boufker H.I., Fayyad-Kazan H., De Bruyn C., Meuleman N., et al. Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A 2010, 16:3537-3546.
31. Najar M., Raicevic G., Id Boufker H., Stamatopoulos B., De Bruyn C., Meuleman N., et al. Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Exp Hematol 2010, 38:922-932.
32. Nasef A., Mathieu N., Chapel A., Frick J., Francois S., Mazurier C., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84:231-237.
33. Romieu-Mourez R., Francois M., Boivin M.N., Bouchentouf M., Spaner D.E., Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. JImmunol 2009, 182:7963-7973.
34. Raicevic G., Rouas R., Najar M., Stordeur P., Boufker H.I., Bron D., et al. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum Immunol 2010, 71:235-244.
35. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
36. Liotta F., Angeli R., Cosmi L., Fili L., Manuelli C., Frosali F., et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008, 26:279-289.
37. Guo J., Loke J., Zheng F., Hong F., Yea S., Fukata M., et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009, 49:960-968.
38. Guo J., Friedman S.L. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair 2010, 21:21.
39. Levitsky J. Operational tolerance: past lessons and future prospects. Liver Transpl 2011, 17:222-232.
40. Wu T.J., Wang Y.C., Wu T.H., Lee C.F., Chan K.M., Lee W.C. Inhibition of allogenic T-cell cytotoxicity by hepatic stellate cell via CD4[U+207A] CD25[U+207A] Foxp3[U+207A] regulatory T cells invitro. Transplant Proc 2012, 44:1055-1059.
41. Charles R., Chou H.S., Wang L., Fung J.J., Lu L., Qian S. Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway. Transplantation 2013, 96:17-24.
42. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24:386-398.
43. Yang H.R., Chou H.S., Gu X., Wang L., Brown K.E., Fung J.J., et al. Mechanistic insights into immunomodulation by hepatic stellate cells in mice: a critical role of interferon-gamma signaling. Hepatology 2009, 50:1981-1991.
44. Mannaerts I., Nuytten N.R., Rogiers V., Vanderkerken K., van Grunsven L.A., Geerts A. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells invitro and invivo. Hepatology 2010, 51:603-614.
45. Thoen L.F., Guimarães E.L., Dollé L., Mannaerts I., Najimi M., Sokal E., et al. Arole for autophagy during hepatic stellate cell activation. JHepatol 2011, 55:1353-1360.
46. Campioni D., Rizzo R., Stignani M., Melchiorri L., Ferrari L., Moretti S., et al. Adecreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. Cytometry B Clin Cytom 2009, 76:225-230.
47. Brisby H., Papadimitriou N., Brantsing C., Bergh P., Lindahl A., Barreto Henriksson H. The presence of local mesenchymal progenitor cells in human degenerated intervertebral discs and possibilities to influence these invitro: a descriptive study in humans. Stem Cells Dev 2013, 22:804-814.
48. Jin H.J., Park S.K., Oh W., Yang Y.S., Kim S.W., Choi S.J. Down-regulation of CD105 is associated with multi-lineage differentiation in human umbilical cord blood-derived mesenchymal stem cells. Biochem Biophys Res Commun 2009, 381:676-681.
49. Briones J., Novelli S., Sierra J. T-cell costimulatory molecules in acute-graft-versus host disease: therapeutic implications. Bone Marrow Res 2011, 976793.
50. Vu M.D., Xiao X., Gao W., Degauque N., Chen M., Kroemer A., et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007, 110:2501-2510.
51. Russell K.C., Phinney D.G., Lacey M.R., Barrilleaux B.L., Meyertholen K.E., O'Connor K.C. Invitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells 2010, 28:788-798.
52. Lepperdinger G. Inflammation and mesenchymal stem cell aging. Curr Opin Immunol 2011, 23:518-524.
53. Nathan C., Muller W.A. Putting the brakes on innate immunity: a regulatory role for CD200?. Nat Immunol 2001, 2:17-19.
54. Gorczynski R.M., Hadidi S., Yu G., Clark D.A. The same immunoregulatory molecules contribute to successful pregnancy and transplantation. Am J Reprod Immunol 2002, 48:18-26.
55. Najar M., Raicevic G., Jebbawi F., De Bruyn C., Meuleman N., Bron D., et al. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett 2012, 146:50-56.
56. Wiendl H., Mitsdoerffer M., Schneider D., Chen L., Lochmuller H., Melms A., et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 2003, 17:1892-1894.
57. Najar M., Raicevic G., Fayyad-Kazan H., De Bruyn C., Bron D., Toungouz M., et al. Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming. Stem Cell Rev 2012, 8:1188-1198.
58. Giuliani M., Fleury M., Vernochet A., Ketroussi F., Clay D., Azzarone B., et al. Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One 2011, 6:e19988.
59. Rasmusson I., Ringden O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76:1208-1213.
60. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24:74-85.
61. Poggi A., Prevosto C., Massaro A.M., Negrini S., Urbani S., Pierri I., et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. JImmunol 2005, 175:6352-6360.
62. Radaeva S., Sun R., Jaruga B., Nguyen V.T., Tian Z., Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006, 130:435-452.
63. Raicevic G., Najar M., Pieters K., De Bruyn C., Meuleman N., Bron D., et al. Inflammation and Toll-like receptor ligation differentially affect the osteogenic potential of human mesenchymal stromal cells depending on their tissue origin. Tissue Eng Part A 2012, 18:1410-1418.
64. Wang B., Trippler M., Pei R., Lu M., Broering R., Gerken G., et al. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. JHepatol 2009, 51:1037-1045.
65. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007, 13:1324-1332.
66. Deng J.F., Geng L., Qian Y.G., Li H., Wang Y., Xie H.Y., et al. The role of toll-like receptors 2 and 4 in acute allograft rejection after liver transplantation. Transplant Proc 2007, 39:3222-3224.